Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Dermatology | Nursing | Oncology | Pathology | Journal

Back to Journal Articles

Inhibition of Immune Pathway May Trigger Melanoma Growth

Last Updated: April 02, 2012.

 

Colocalization of immune inhibitory B7-H1 and tumor-infiltrating lymphocytes seen in melanocytes

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Melanocyte expression of an immune inhibitory molecule, B7-H1, is associated with the presence of tumor-infiltrating lymphocytes, according to a study published in the March 28 issue of Science Translational Medicine.

MONDAY, April 2 (HealthDay News) -- Melanocyte expression of an immune inhibitory molecule, B7-H1, is associated with the presence of tumor-infiltrating lymphocytes (TILs), according to a study published in the March 28 issue of Science Translational Medicine.

In an effort to understand the association between B7-H1 and TILs, Janis M. Taube, M.D., from the Johns Hopkins Medical Institutions in Baltimore, and colleagues examined the expression of B7-H1 in melanocytes and primary and metastatic melanomas.

The researchers found that 98 percent of B7-H1+ tumors, and only 28 percent of B7-H1− tumors, were associated with TILs. The inflammatory cytokine interferon-γ, which induces B7-H1, was found at the interface of B7-H1+ tumors, but not B7-H1− tumors. The investigators theorized that TILs may secrete interferon-γ, triggering their own inhibition. Consistent with this, patients with B7-H1+ metastatic melanoma survived significantly longer than patients with B7-H1− metastatic melanomas.

"Induction of the B7-H1/PD-1 pathway may represent an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous antitumor activity and may explain how melanomas escape immune destruction despite endogenous antitumor immune responses," Taube and colleagues conclude. "These observations suggest that therapies that block this pathway may benefit patients with B7-H1+ tumors."

Several authors disclosed receiving research support from Bristol-Myers Squibb.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Malodorous Urine Often Reported for Infants With UTI Next: AACR: Metformin May Benefit Prostate Cancer Patients

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.